The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

• Published in: Bone marrow transplantation (Basingstoke) 2021-01, Vol.56 (1), p.30-37
• Main Authors: Selberg, Lorenz, Stadtherr, Peter, Dietrich, Sascha, Tran, T. Hien, Luft, Thomas, Hegenbart, Ute, Bondong, Andrea, Meissner, Julia, Liebers, Nora, Schmitt, Michael, Ho, Anthony Dick, Müller-Tidow, Carsten, Dreger, Peter
• Format: Article
• Language: English
• Subjects: 692/308/2171; 692/308/2779; B-cell lymphoma; Care and treatment; Cell Biology; Diagnosis; Hematology; Hematopoietic stem cells; Internal Medicine; Lymphocytes B; Lymphocytes T; Lymphoma; Mantle cell lymphoma; Medicine; Medicine & Public Health; Non-Hodgkin's lymphoma; Non-Hodgkin's lymphomas; Patient outcomes; Public Health; Searching; Stem cell transplantation; Stem Cells; Survival; T-cell lymphoma; Transplantation; Transplants & implants
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/s41409-020-0976-4

Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-transplant (ITT). Included were all consecutive patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and peripheral T-cell lymphoma (PTCL) for whom a donor search was performed between 2004 and 2018. Primary endpoint was overall survival (OS) measured from search initiation. A donor search was initiated for 189 patients (DLBCL 61, FL 32, MCL 43, and PTCL 53), with 76% of the patients having active disease. OS at 5 years after search initiation for DLBCL, FL, MCL, and PTCL was 26%, 44%, 52%, and 50%, respectively. AlloHCT was performed in 137 patients (72%; DLBCL 64%). Main reason for not undergoing alloHCT was disease progression, whereas donor unavailability accounted for only 4% of pretransplantation failures. These results suggest that survival of patients with r/r NHL entering the alloHCT route may be overestimated by a factor of 1.2–1.4 if based on actually transplanted patients only. This effect should be taken into account when using alloHCT as benchmark for new therapeutic approaches for the treatment of poor-risk NHL.